THE EFFICIENCY OF BIO PRODUCTION IN ROMANIA

This is a study related to organic agriculture efficiency in Romania. The study made in the year of 2004 intended to assess the structure and production’s level on this field of agriculture. As resulted following this research the efficiency (Yields/ha)in the field of organic production is not less than conventional efficiency. In a way surprisingly is the conclusion that the efficiency (Yields/ha) is not increasing on bigger cultivated surfaces

Search for particle–vibration coupling in 65Cu

The lifetime of the 9/2 + state of 65 Cu, at 2534 keV, has been measured by fast timing techniques, in order to establish wether such state arises from a weak coupling between a p3=2 proton and the 3 octupole vibration at 3.56 MeV in the 64 Ni core. The 65 Cu nucleus was populated by the reaction 7 Li + 64 Ni at 32 MeV, at the Horia Hu- lubei National Institute of Physics and Nuclear Engineering (NIPNE) in Bucharest, and its -decay was detected by the ROSPHERE array. The measured lifetime coresponds to a B(E3) reduced transition probability to the ground state equal to 8.89 W.u., in agreement with theoretical predictions in the weak coupling limit

Normal and intruder configurations in Si- 34 populated in the beta(-) decay of Mg-34 and Al-34

The structure of Si-34 was studied through gamma spectroscopy separately in the beta(-) decays of Mg-34 and Al-34 at the ISOLDE facility of CERN. Different configurations in Si-34 were populated independently from the two recently identified beta-decaying states in Al-34 having spin-parity assignments J(pi) = 4(-) dominated by the normal configuration pi(d(5/2))(-1) circle times nu(f(7/2)) and J(pi) = 1(+) by the intruder configuration pi(d(5/2))(-1) circle times nu(d(3/2))(-1) (f(7/2))(2). The paper reports on spectroscopic properties of Si-34 such as an extended level scheme, spin and parity assignments based on log(ft) values and gamma-ray branching ratios, absolute beta feeding intensities, and neutron emission probabilities. A total of 11 newly identified levels and 26 transitions were added to the previously known level scheme of Si-34. Large scale shell-model calculations using the SDPF-U-MIX interaction, able to treat higher order intruder configurations, are compared with the new results and conclusions are drawn concerning the predictive power of SDPF-U-MIX, the N = 20 shell gap, the level of mixing between normal and intruder configurations for the 0(1)(+), 0(2)(+), and 2(1)(+) states, and the absence of triaxial deformation in Si-3(4).Peer reviewe

Half-life of the yrast 2

The half-life of the yrast I π = 2+ state in the neutron-rich nucleus 188W has been measured using fast-timing techniques with the HPGe and LaBr3:Ce array at the National Institute of Physics and Nuclear Engineering, Bucharest. The resulting value of t1/2 = 0.87(12) ns is equivalent to a reduced transition probability of B(E2; 2+ 1 → 0+ 1 ) = 85(12) W.u. for this transition. The B(E2; 2+ 1 → 0+ 1 ) is compared to neighboring tungsten isotopes and nuclei in the Hf, Os, and Pt isotopic chains. Woods-Saxon potential energy surface (PES) calculations have been performed for nuclei in the tungsten isotopic chain and predict prolate deformed minima with rapidly increasing γ softness for 184–192W and an oblate minimum for 194W

Safety of intravenous ferric carboxymaltose versus oral iron in patients with nondialysis-dependent CKD: an analysis of the 1-year FIND-CKD trial.

Background: The evidence base regarding the safety of intravenous (IV) iron therapy in patients with chronic kidney disease (CKD) is incomplete and largely based on small studies of relatively short duration. Methods: FIND-CKD (ClinicalTrials.gov number NCT00994318) was a 1-year, open-label, multicenter, prospective study of patients with nondialysis-dependent CKD, anemia and iron deficiency randomized (1:1:2) to IV ferric carboxymaltose (FCM), targeting higher (400-600 µg/L) or lower (100-200 µg/L) ferritin, or oral iron. A post hoc analysis of adverse event rates per 100 patient-years was performed to assess the safety of FCM versus oral iron over an extended period. Results: The safety population included 616 patients. The incidence of one or more adverse events was 91.0, 100.0 and 105.0 per 100 patient-years in the high ferritin FCM, low ferritin FCM and oral iron groups, respectively. The incidence of adverse events with a suspected relation to study drug was 15.9, 17.8 and 36.7 per 100 patient-years in the three groups; for serious adverse events, the incidence was 28.2, 27.9 and 24.3 per 100 patient-years. The incidence of cardiac disorders and infections was similar between groups. At least one ferritin level ≥800 µg/L occurred in 26.6% of high ferritin FCM patients, with no associated increase in adverse events. No patient with ferritin ≥800 µg/L discontinued the study drug due to adverse events. Estimated glomerular filtration rate remained the stable in all groups. Conclusions: These results further support the conclusion that correction of iron deficiency anemia with IV FCM is safe in patients with nondialysis-dependent CKD

Effect of aliskiren on post-discharge outcomes among diabetic and non-diabetic patients hospitalized for heart failure: insights from the ASTRONAUT trial

Aims The objective of the Aliskiren Trial on Acute Heart Failure Outcomes (ASTRONAUT) was to determine whether aliskiren, a direct renin inhibitor, would improve post-discharge outcomes in patients with hospitalization for heart failure (HHF) with reduced ejection fraction. Pre-specified subgroup analyses suggested potential heterogeneity in post-discharge outcomes with aliskiren in patients with and without baseline diabetes mellitus (DM). Methods and results ASTRONAUT included 953 patients without DM (aliskiren 489; placebo 464) and 662 patients with DM (aliskiren 319; placebo 343) (as reported by study investigators). Study endpoints included the first occurrence of cardiovascular death or HHF within 6 and 12 months, all-cause death within 6 and 12 months, and change from baseline in N-terminal pro-B-type natriuretic peptide (NT-proBNP) at 1, 6, and 12 months. Data regarding risk of hyperkalaemia, renal impairment, and hypotension, and changes in additional serum biomarkers were collected. The effect of aliskiren on cardiovascular death or HHF within 6 months (primary endpoint) did not significantly differ by baseline DM status (P = 0.08 for interaction), but reached statistical significance at 12 months (non-DM: HR: 0.80, 95% CI: 0.64-0.99; DM: HR: 1.16, 95% CI: 0.91-1.47; P = 0.03 for interaction). Risk of 12-month all-cause death with aliskiren significantly differed by the presence of baseline DM (non-DM: HR: 0.69, 95% CI: 0.50-0.94; DM: HR: 1.64, 95% CI: 1.15-2.33; P < 0.01 for interaction). Among non-diabetics, aliskiren significantly reduced NT-proBNP through 6 months and plasma troponin I and aldosterone through 12 months, as compared to placebo. Among diabetic patients, aliskiren reduced plasma troponin I and aldosterone relative to placebo through 1 month only. There was a trend towards differing risk of post-baseline potassium ≥6 mmol/L with aliskiren by underlying DM status (non-DM: HR: 1.17, 95% CI: 0.71-1.93; DM: HR: 2.39, 95% CI: 1.30-4.42; P = 0.07 for interaction). Conclusion This pre-specified subgroup analysis from the ASTRONAUT trial generates the hypothesis that the addition of aliskiren to standard HHF therapy in non-diabetic patients is generally well-tolerated and improves post-discharge outcomes and biomarker profiles. In contrast, diabetic patients receiving aliskiren appear to have worse post-discharge outcomes. Future prospective investigations are needed to confirm potential benefits of renin inhibition in a large cohort of HHF patients without D

Differential cross section measurements for the production of a W boson in association with jets in proton–proton collisions at √s = 7 TeV

Measurements are reported of differential cross sections for the production of a W boson, which decays into a muon and a neutrino, in association with jets, as a function of several variables, including the transverse momenta (pT) and pseudorapidities of the four leading jets, the scalar sum of jet transverse momenta (HT), and the difference in azimuthal angle between the directions of each jet and the muon. The data sample of pp collisions at a centre-of-mass energy of 7 TeV was collected with the CMS detector at the LHC and corresponds to an integrated luminosity of 5.0 fb[superscript −1]. The measured cross sections are compared to predictions from Monte Carlo generators, MadGraph + pythia and sherpa, and to next-to-leading-order calculations from BlackHat + sherpa. The differential cross sections are found to be in agreement with the predictions, apart from the pT distributions of the leading jets at high pT values, the distributions of the HT at high-HT and low jet multiplicity, and the distribution of the difference in azimuthal angle between the leading jet and the muon at low values.United States. Dept. of EnergyNational Science Foundation (U.S.)Alfred P. Sloan Foundatio

Rising rural body-mass index is the main driver of the global obesity epidemic in adults

Body-mass index (BMI) has increased steadily in most countries in parallel with a rise in the proportion of the population who live in cities(.)(1,2) This has led to a widely reported view that urbanization is one of the most important drivers of the global rise in obesity(3-6). Here we use 2,009 population-based studies, with measurements of height and weight in more than 112 million adults, to report national, regional and global trends in mean BMI segregated by place of residence (a rural or urban area) from 1985 to 2017. We show that, contrary to the dominant paradigm, more than 55% of the global rise in mean BMI from 1985 to 2017-and more than 80% in some low- and middle-income regions-was due to increases in BMI in rural areas. This large contribution stems from the fact that, with the exception of women in sub-Saharan Africa, BMI is increasing at the same rate or faster in rural areas than in cities in low- and middle-income regions. These trends have in turn resulted in a closing-and in some countries reversal-of the gap in BMI between urban and rural areas in low- and middle-income countries, especially for women. In high-income and industrialized countries, we noted a persistently higher rural BMI, especially for women. There is an urgent need for an integrated approach to rural nutrition that enhances financial and physical access to healthy foods, to avoid replacing the rural undernutrition disadvantage in poor countries with a more general malnutrition disadvantage that entails excessive consumption of low-quality calories.Peer reviewe